Type 2 Diabetes Mellitus Clinical Trial
Official title:
Diabetes em Movimento® - Community-based Lifestyle Intervention Program for Patients With Type 2 Diabetes: Effects on Health and Well-being
NCT number | NCT02631902 |
Other study ID # | UTras |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2015 |
Est. completion date | December 2018 |
Verified date | August 2019 |
Source | University of Trás-os-Montes and Alto Douro |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Type 2 diabetes is a chronic disease that affects approximately 13% of Portuguese population and is associated with a high cardiovascular mortality by coronary artery disease and cerebrovascular disease and with a serious decline on well-being. Lifestyle changes are widely recommended to the control of type 2 diabetes and its complications. This study aims to analyse the effects of different community-based lifestyle programs (exercise or exercise plus dietary intervention) on health and well-being in patients with type 2 diabetes.
Status | Completed |
Enrollment | 90 |
Est. completion date | December 2018 |
Est. primary completion date | June 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Patients with diagnosed type 2 diabetes at least for six months; 2. Both genders; 3. Aged between 50 and 80 years old; 4. Non-smokers; 5. Not engaged in supervised exercise; 6. Community-dwelling; 7. Medical recommendation for lifestyle intervention; 8. Known medical history; 9. Diabetes complications under medical control (poor metabolic control, diabetic foot, diabetic retinopathy, diabetic nephropathy and diabetic autonomic neuropathy; 10. No cardiovascular, respiratory and musculoskeletal contraindications to exercise; 11. No gait and balance problems; 12. Not taking insulin or sulfonylureas for less than three months; 13. Volunteer participation with signed informed consent. Exclusion Criteria: 1. Participation in another supervised exercise program during the study; 2. Participation in another supervised dietary intervention during the study; 3. Aggravation of a diabetes complication or another major health problem; |
Country | Name | City | State |
---|---|---|---|
Portugal | University of Trás-os-Montes e Alto Douro | Vila Real |
Lead Sponsor | Collaborator |
---|---|
University of Trás-os-Montes and Alto Douro |
Portugal,
Matos M, Mendes R, Silva AB, Sousa N. Physical activity and exercise on diabetic foot related outcomes: A systematic review. Diabetes Res Clin Pract. 2018 May;139:81-90. doi: 10.1016/j.diabres.2018.02.020. Epub 2018 Feb 23. Review. — View Citation
Vasconcelos C, Almeida A, Cabral M, Ramos E, Mendes R. The Impact of a Community-Based Food Education Program on Nutrition-Related Knowledge in Middle-Aged and Older Patients with Type 2 Diabetes: Results of a Pilot Randomized Controlled Trial. Int J Envi — View Citation
Vasconcelos C, Almeida A, Sá C, Viana J, Cabral M, Ramos E, Mendes R. Nutrition-related knowledge and its determinants in middle-aged and older patients with type 2 diabetes. Prim Care Diabetes. 2019 Jul 23. pii: S1751-9918(18)30418-2. doi: 10.1016/j.pcd. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiovascular Risk | UKPDS Risk Engine | Baseline, 9 and 21 months | |
Primary | Health-Related Quality of Life | SF-36 Health Survey | Baseline, 9 and 21 months | |
Secondary | Food Literacy | General Nutrition Knowledge Questionnaire for Adults | Baseline, 9 and 21 months | |
Secondary | Dietary Pattern | 3-day Food Record | Baseline, 9 and 21 months | |
Secondary | Physical Fitness | Physical Fitness Test Battery | Baseline, 9 and 21 months | |
Secondary | Diabetic Foot Risk | International Working Group on the Diabetic Foot Risk Classification) | Baseline, 9 and 21 months | |
Secondary | Exercise-Related Adverse Events | Number of acute injuries or adverse events during exercise sessions | Baseline, 9 and 21 months | |
Secondary | Systolic Blood Pressure | mmHg | Baseline, 9 and 21 months | |
Secondary | Diastolic Blood Pressure | mmHg | Baseline, 9 and 21 months | |
Secondary | Glycemic Control | Glycated Hemoglobin | Baseline, 9 and 21 months | |
Secondary | Fast blood glucose | mg/dL | Baseline, 9 and 21 months | |
Secondary | Total Cholesterol | mg/dL | Baseline, 9 and 21 months | |
Secondary | Body Fat Mass | Bioelectrical impedance analysis | Baseline, 9 and 21 months | |
Secondary | Body Lean Mass | Bioelectrical impedance analysis | Baseline, 9 and 21 months | |
Secondary | Quality of Sleep | Pittsburgh Sleep Quality Index | Baseline, 9 and 21 months | |
Secondary | Symptoms of Anxiety and Depression | Hospital Anxiety and Depression Scale | Baseline, 9 and 21 months | |
Secondary | Chronic Pain | Brief Pain Inventory Questionnaire | Baseline, 9 and 21 months | |
Secondary | Diabetes-Dependent Quality of Life | Audit of Diabetes-Dependent Quality of Life Questionnaire | Baseline, 9 and 21 months | |
Secondary | Habitual Physical Activity | International Physical Activity Questionnaire | Baseline, 9 and 21 months | |
Secondary | Waist Circumference | cm | Baseline, 9 and 21 months | |
Secondary | Falls Risk | Timed Up and Go Test | Baseline, 9 and 21 months | |
Secondary | Sitting-Time | Hours per day | Baseline, 9 and 21 months | |
Secondary | Energy Expenditure | kcal/kg/min | Baseline, 9 and 21 months | |
Secondary | Body Mass Index | kg/m2 | Baseline, 9 and 21 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|